Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2304-2310

  Santolaya, María Elena ^a   O'Ryan, Miguel L ^b   Valenzuela, María Teresa ^c   Prado, Valeria ^b   Vergara, Rodrigo F ^d   Muñoz, Alma ^e   Toneatto, Daniela ^f   Graña, Gabriela ^f   Wang, Huajun ^f   Dull, Peter M ^f  

^a HOSPITAL LUIS CALVO MACKENNA   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD DE LOS ANDES   (Chile)

^d UNIVERSIDAD DE VALPARAÍSO   (Chile)

^e Centro para Vacunas en Desarrollo Chile   (Chile)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adolescents; Antibodies; Meningococcal; Persistence; Serogroup B; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; PLACEBO; 4CMENB VACCINE; BACTERIUM ANTIBODY; COMPLEMENT;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; NORMAL HUMAN; TREATMENT DURATION; BLOOD; CHILD; IMMUNOLOGY; SERUM BACTERICIDAL ACTIVITY; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; YOUNG ADULT;

EID: 84887443034     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25505     Document Type: Article

References (16)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID: 19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
2. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50(Suppl 2):S54-65; PMID: 20144017; http://dx.doi.org/10.1086/648966
3. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccha-ride-tetanus toxoid conjugates. J Immunol 1981; 127: 1011-8; PMID: 6790606 (Pubitemid 11051148)
4. Jennings HJ, Gamian A, Ashton FE. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 1987; 165: 1207-11; PMID: 2435835; http://dx.doi.org/10.1084/jem.165.4.1207 (Pubitemid 17064516)
5. Zollinger WD, Poolman JT, Maiden MCJ. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines 2011; 10: 559-61; PMID: 21604975; http://dx.doi.org/10.1586/er v.11. 41
6. Tappero J W, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 sero-group B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520-7; PMID: 10227322; http://dx.doi.org/10.1001/jama.281.16.1520 (Pubitemid 29200936)
7. Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningo-coccus by whole-genome sequencing. Science 2000; 287: 1816-20; PMID: 10710308; http://dx.doi.org/10.1126/science.287.5459.1816
8. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medi-cines/002333/smops/Positive/human-smop-000447.jsp&mid= WC0b01ac058001d127. jsp&mid=WC0b01ac058001d127. Accessed 18 Feb 2 013.
9. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al.; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381: 825-35; PMID: 23324563; http://dx.doi.org/10.1016/S0140-6736 (12 ) 61961-8
10. Toneatto D, Oster P, deBoer AC, Emerson A, Santos GF, Ypma E, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 2011; 7: 781-91; PMID: 21734467; http://dx.doi.org/10.4161/h v.7. 7.159 9 7
11. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379: 617-24; PMID: 22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3
12. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-6; PMID: 19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
13. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107: 19490-5; PMID: 20962280; http://dx.doi.org/10.1073/pnas.1013758107
14. Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013; February 13, 2013 http://dx.doi.org/10.1016/S1473-3099(13)70006-9.
15. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningo-coccal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197: 737-43; PMID: 18271745; http://dx.doi.org/10.1086/527401 (Pubitemid 351364476)
16. Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21: 734-7; PMID: 12531351; http://dx.doi.org/10.1016/S0264-410X(02)00591-1 (Pubitemid 36091989)